Modality
Small Molecule
MOA
BCL-2i
Target
FGFR
Pathway
Tau
Bladder CaHemophilia A
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
Jul 2019
→ Mar 2029
Phase 1Current
NCT05777343
1,880 pts·Hemophilia A
2019-07→2029-03·Recruiting
1,880 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-03-032.9y awayPh2 Data· Hemophilia A
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1/2
Recruit…
Catalysts
Ph2 Data
2029-03-03 · 2.9y away
Hemophilia A
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05777343 | Phase 1/2 | Hemophilia A | Recruiting | 1880 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |